Company news

Zevra Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Zevra Therapeutics to Participate in the Citizens Life Science Conference

April 30, 2025

Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders

April 20, 2025

Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

April 16, 2025

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

April 6, 2025

Zevra Therapeutics Files Preliminary Proxy

March 30, 2025

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

March 10, 2025

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

February 27, 2025

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

February 26, 2025

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

February 25, 2025

Zevra to Participate at Upcoming Investor Conferences

February 23, 2025

Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™

January 29, 2025

Zevra Therapeutics to Participate at Upcoming Investor Conferences

January 28, 2025

Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

December 16, 2024

Zevra Therapeutics Announces Organizational Changes

December 5, 2024

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

November 20, 2024

Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates

November 11, 2024

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

November 10, 2024

Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13

November 5, 2024

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

October 30, 2024

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

October 9, 2024

NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders

October 8, 2024

Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024

September 23, 2024

Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

September 19, 2024

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

September 5, 2024

Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

August 12, 2024

Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock

August 7, 2024

Zevra Therapeutics Announces Proposed Public Offering of Common Stock

August 7, 2024

Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth Conference

August 6, 2024

FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

August 1, 2024

Zevra Therapeutics to Report Second Quarter 2024 Financial Results

July 29, 2024

Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

July 8, 2024

Zevra Therapeutics Expands Executive Leadership Team

June 24, 2024

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders

June 17, 2024

Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting

June 2, 2024

Zevra Therapeutics to Participate at Upcoming Investor Events

May 8, 2024

Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

May 7, 2024

Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024

April 30, 2024

Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024

April 28, 2024

Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting

April 14, 2024

Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility

April 9, 2024

Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

March 27, 2024

Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

March 25, 2024

Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

March 24, 2024

Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024

March 17, 2024

Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

March 3, 2024

Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 5, 2024

Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors

January 22, 2024

Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

January 7, 2024

Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer

January 3, 2024

Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration

December 26, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 12 calls. Every call is listed under its year.

Decks

The 5 newest of 61 decks. Every deck is listed under its year.